Data

A phase II study evaluating efficacy and safety of Ipilimumab and Nivolumab with neoadjuvant weekly paclitaxel after anthracycline based chemotherapy in high-risk primary triple negative breast cancer, followed by definitive surgery and one year total duration of Nivolumab (BCT 1702 CHARIOT)

Health Data Australia Contributor Records
Loi, Sherene ; Breast Cancer Trials (BCT) ; Breast Cancer Trials (BCT)
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.58080/6MX7-NV49&rft.title=A phase II study evaluating efficacy and safety of Ipilimumab and Nivolumab with neoadjuvant weekly paclitaxel after anthracycline based chemotherapy in high-risk primary triple negative breast cancer, followed by definitive surgery and one year total duration of Nivolumab (BCT 1702 CHARIOT)&rft.identifier=http://doi.org/10.58080/6MX7-NV49&rft.publisher=Breast Cancer Trials (BCT)&rft.description=* Dataset of 34 patients with high risk primary triple negative breast cancer suitable for neoadjuvant treatment after treatment with 4 cycles anthracycline-based chemotherapy. * Study treatment for 12 weeks with Nivolumab for 6 doses; Ipilimumab for 2 doses; paclitaxel weekly for 12 doses. * Surgery withn 4 weeks of last paclitaxel dose. * Followed by nivolumab every 4 weeks for up to 1 year. * Survival follow up at 24 months and 36 months from cycle 1 day 1. * pCR, residual diseae, objective response rate data. * Safety/toxicity, event free survival, overall survival data. * ctDNA data.&rft.creator=Loi, Sherene &rft.creator=Breast Cancer Trials (BCT) &rft.creator=Breast Cancer Trials (BCT) &rft.date=2024&rft.relation=https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12617000651381&rft_subject=Cancer therapy (excl. chemotherapy and radiation therapy)&rft.type=dataset&rft.language=English Access the data
Cite Saved to MyRDA Save to MyRDA

Full description

* Dataset of 34 patients with high risk primary triple negative breast cancer suitable for neoadjuvant treatment after treatment with 4 cycles anthracycline-based chemotherapy. * Study treatment for 12 weeks with Nivolumab for 6 doses; Ipilimumab for 2 doses; paclitaxel weekly for 12 doses. * Surgery withn 4 weeks of last paclitaxel dose. * Followed by nivolumab every 4 weeks for up to 1 year. * Survival follow up at 24 months and 36 months from cycle 1 day 1. * pCR, residual diseae, objective response rate data. * Safety/toxicity, event free survival, overall survival data. * ctDNA data.

Notes

HeSANDA 1.0.0

Issued: 2023

Available: 2024

This dataset is part of a larger collection

Click to explore relationships graph
Help

Related Publications

Related Organisations

Related People

Subjects
Cancer therapy (excl. chemotherapy and radiation therapy) |

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Other Information
Breast Cancer Trials (BCT)

ROR : https://ror.org/00j1vsg87

Identifiers
Similar data you may be interested in: